company background image
GEKA logo

Genomma Lab Internacional. de DB:GEKA Stock Report

Last Price

€0.81

Market Cap

€775.5m

7D

3.2%

1Y

15.7%

Updated

25 Mar, 2024

Data

Company Financials +

Genomma Lab Internacional, S.A.B. de C.V.

DB:GEKA Stock Report

Market Cap: €775.5m

GEKA Stock Overview

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America.

GEKA fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance2/6
Financial Health5/6
Dividends4/6

Genomma Lab Internacional, S.A.B. de C.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genomma Lab Internacional. de
Historical stock prices
Current Share PriceMex$0.81
52 Week HighMex$0.81
52 Week LowMex$0.66
Beta0.47
1 Month Change11.72%
3 Month Change12.50%
1 Year Change15.71%
3 Year Change-4.14%
5 Year Change27.56%
Change since IPO63.64%

Recent News & Updates

Recent updates

Shareholder Returns

GEKADE PharmaceuticalsDE Market
7D3.2%2.1%1.6%
1Y15.7%-26.3%6.4%

Return vs Industry: GEKA exceeded the German Pharmaceuticals industry which returned -25.6% over the past year.

Return vs Market: GEKA exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is GEKA's price volatile compared to industry and market?
GEKA volatility
GEKA Average Weekly Movement5.7%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: GEKA has not had significant price volatility in the past 3 months.

Volatility Over Time: GEKA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19961,783Juan Marco Sparvierihttps://www.genommalab.com

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.

Genomma Lab Internacional, S.A.B. de C.V. Fundamentals Summary

How do Genomma Lab Internacional. de's earnings and revenue compare to its market cap?
GEKA fundamental statistics
Market cap€775.46m
Earnings (TTM)€56.98m
Revenue (TTM)€910.43m

13.6x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GEKA income statement (TTM)
RevenueMex$16.47b
Cost of RevenueMex$6.38b
Gross ProfitMex$10.08b
Other ExpensesMex$9.05b
EarningsMex$1.03b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.11
Gross Margin61.23%
Net Profit Margin6.26%
Debt/Equity Ratio66.0%

How did GEKA perform over the long term?

See historical performance and comparison

Dividends

5.2%

Current Dividend Yield

68%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.